Peterson James, Galarza Katherine, Bchir Siham, Zocchetti Celine, Bertrand-Gerentes Isabelle, Zambrano Betzana
J. Lewis Research, Salt Lake City, UT, USA.
Scientific & Medical Affairs, Sanofi, Swiftwater, PA, USA.
Pediatr Res. 2024 Dec 13. doi: 10.1038/s41390-024-03760-w.
Immune persistence following primary vaccination with a single dose of meningococcal quadrivalent conjugate vaccines, MenACYW-TT/MCV4-CRM, at age 10-12 years was demonstrated. Most participants primed with MenACYW-TT and MCV4-CRM maintained seroprotective titers against all serogroups, suggesting continued protection. Priming with MenACYW-TT resulted in higher persistent titers for serogroups C, W, and Y than MCV4-CRM. A MenACYW-TT booster induced a robust immune response; almost all participants achieved seroprotection against all serogroups. This analysis supports the ACIP recommendations for routine administration of a primary dose of a meningococcal ACWY conjugate vaccine at 11-12 years, with a booster dose at 16 years.
研究证实了10至12岁儿童单次接种一剂四价脑膜炎球菌结合疫苗MenACYW-TT/MCV4-CRM后的免疫持久性。大多数接种MenACYW-TT和MCV4-CRM的参与者对所有血清群均维持血清保护滴度，提示持续的保护作用。接种MenACYW-TT后，C、W和Y血清群的持久性滴度高于MCV4-CRM。一剂MenACYW-TT加强免疫可诱导强烈的免疫反应；几乎所有参与者对所有血清群均获得血清保护。该分析支持美国免疫实践咨询委员会（ACIP）关于在11至12岁常规接种一剂脑膜炎球菌ACWY结合疫苗，并在16岁时接种加强剂的建议。
